Treatment in Patients with Refractory ITP
Eight out of 11 studies discussed the treatment for pediatric patients with rITP. Treatment modalities included splenectomy9,11, rituximab9,13,16–18, romiplostim14, and dapsone8 (Table 2). The most frequent treatment used in the treatment of rITP was rituximab; the reported efficacy of rituximab in rITP was wide-ranging from 0-72%.9,13,17,18 For splenectomy, eight out of 13 patients achieved complete remission, 2 partial remission, and 3 had no response.9,11